Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus ociperlimab versus tislelizumab plus placebo in second-line PD-L1-positive advanced esophageal squamous cell carcinoma
2020-004658-32Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tislelizumab plus ociperlimab with Tislelizumab plus placebo (2 arms). Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
tislelizumabociperlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-004658-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004658-32.